VIVEK PANWAR

@chitkara.edu.in

Assistant Professor School of Pharmacy, Chitkara University HP
Chitkara School of Pharmacy Chitkara University HP

VIVEK PANWAR


                     Download Compact PDF  
https://researchid.co/vivekpanwar

EDUCATION

B Pharmacy (2012-2016), M Pharmacy (2016-2018), PhD (2020-2024)

RESEARCH, TEACHING, or OTHER INTERESTS

Cancer Research, Drug Discovery, Pharmaceutical Science, Organic Chemistry
14

Scopus Publications

1163

Scholar Citations

5

Scholar h-index

3

Scholar i10-index

Scopus Publications

  • Biological Activities and Metabolomic Profiling of Cymbopogon citratus (DC.) Stapf Leaf Extract Using LC–MS Analysis
    Nidhi Gupta, Nitin Sharma, Vivek Panwar, Vikas Kumar, Wubetie Adnew
    Journal of Chemistry, 2026
    Cymbopogon citratus (DC.) Stapf is widely recognized for its medicinal and aromatic effects. The present study examines the phytochemical composition, biological properties, and metabolomic profiling of C. citratus leaf extract using liquid chromatography–mass spectrometry (LC–MS). The crude 70% methanolic extract (ME) exhibited high total phenolic and flavonoid contents and demonstrated antioxidant activity, as evidenced by DPPH radical scavenging (IC 50 : 12.29 ± 2.10 μg/mL) and ferric reducing antioxidant power (FRAP, IC 50 : 26.68 ± 1.56 μM Fe (II) equivalents). ME also exhibited strong in vitro antidiabetic activity by inhibiting α‐amylase (IC 50 : 6.34 ± 0.15 μg/mL), α‐glucosidase (IC 50 : 63.07 ± 6.33 μg/mL), and dipeptidyl peptidase‐IV (DPP‐IV; IC 50 : 319.50 ± 29.96 μg/mL). Cytotoxicity assessment using L6 myoblasts indicated low cytotoxicity of ME at the tested concentrations. The LC/MS‐based metabolomic analysis of ME revealed the presence of various bioactive metabolites, predominantly phenolic acid, flavonoids, and triterpenes, which may underlie the observed bioactivities. Thus, integrated phytochemical analysis, bioactivity, and metabolomic findings support the nutraceutical potential of C. citratus and its prospective application in functional food preparations aimed to improve metabolic health.
  • Phytochemical profiling, antioxidant, antidiabetic, and cytotoxic evaluation of wheatgrass (Triticum aestivum L.)
    Nidhi Gupta, Nitin Sharma, Vivek Panwar, Vikas Kumar, Wubetie Adnew
    Discover Food, 2025
    Wheatgrass ( Triticum aestivum L.) is valued for its rich bioactive composition and potential therapeutic benefits. This study investigates the phytochemical composition, antioxidant, antidiabetic, and cytotoxic properties of wheatgrass extract. Methanolic (ME) and n-hexane (HE) extracts of wheatgrass (WG) were evaluated for phytochemical composition, with ME demonstrating higher total phenolic content (32.41 ± 1.71 mg/g GAE) and flavonoid content (48.04 ± 1.50 mg/g RE). ME exhibited strong antioxidant activity with IC 50 of 20.21 ± 1.24 µg/mL and 55.25 ± 0.75 µM Fe (II) equivalents with DPPH and FRAP assay, respectively . ME also displayed promising antidiabetic potential with IC 50 of 6.57 ± 0.38 µg/mL, 134.54 ± 20.70 µg/mL, and 414.53 ± 54.15 µg/mL with α-amylase, α-glucosidase, and DPP (IV) inhibitory assays, respectively . LC-MS/MS analysis of ME revealed the presence of 40 secondary metabolites, including apigenin, luteolin, quercetin, and ascorbic acid, correlating with observed bioactivities. The cytotoxicity assay (IC 50 :519.1 ± 0.08 µg/mL), confirmed the safety of WG at therapeutic concentrations. A positive correlation between phenolic contents and bioactivities underscores WG as a natural antioxidant and antidiabetic agent. This study highlights the potential of WG as a functional food or phytopharmaceutical candidate, warranting further in vivo and clinical studies to confirm its efficacy and safety.
  • Molecular medicine and biomedical research in the era of precision medicine: New technologies, lifestyle interventions and personalized drug therapies for patient care
    R.C. Sobti, Vivek Panwar, Deepak Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine New Technologies and Personalized Drug Therapies for Patient Care, 2025
  • Recent advances in mammalian target of rapamycin targeted heterocyclic scaffolds as anticancer agents
    Vivek Panwar, Manjunath Ghate, Raj Kumar, Deepak Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine New Technologies and Personalized Drug Therapies for Patient Care, 2025
  • Application of Bioinformatics in Receptor Biology and Drug Discovery
    Vivek Panwar, H. Lalhlenmawia, Dheeraj Bisht, Rajeshwar Kamal Kant Arya, Deepak Kumar
    Receptors, 2025
  • Design, synthesis, in silico, anticancer evaluations of N-acylhydrazone derivatives as STAT3 inhibitors
    Vivek Panwar, Yajat Rohila, Aishwarya Singh, Meenakshi, Bhavana Singh, Manoj K Gupta, Manoj Garg, Deepak Kumar
    Future Medicinal Chemistry, 2025
    AIM: -acylhydrazone derivatives were synthesized, evaluated in-vitro and further subjected to cell cycle analysis, cell apoptosis, western bloting, and in-silico analysis targeting STAT3. MATERIALS AND METHODS: . RESULTS AND CONCLUSION: treatment induced G1/S arrest marked decrease in G2/M and displayed a significant increase in the apoptosis of MIA PaCa-2 cells. 5 l treatment significantly inhibited the phosphorylated level STAT3 and JAK1. In-silico studies confirm the binding affinity and stability and further synthetic modifications and biological investigations can be done to explore the medicinal potential of the derivatives in future.
  • Synthesis, Evaluation and Docking Studies of Disubstituted N-Heterocyclic Derivatives as Anticancer Agents
    Sreenivasulu Reddy Gopireddy, Vivek Panwar, Ankan Sarkar, Manish Jain, Kothapalli Bannoth Tejaswini, Kothapalli Bannoth Chandrasekhar, Deepak Kumar
    Chemistry and Biodiversity, 2024
    Cancer is a chronic disease reported with alarming rates of mortalities every year. Herein, we reported the synthesis of nitrogen based novel heterocyclic disubstituted derivatives and evaluated them against L929 and A549 cell lines using MTT assay. Among all, 6a2 and 6c1 were significantly active against L929 with IC50 value of 2.61±9.58 and 2.64±8.97 μg/mL respectively. Compounds 6a2 and 6c1 were also active against A549 with IC50 value of 2.36±9.20 and 2.43±6.28 μg/mL respectively and were found to be more potent than the standard drug Doxorubicin. A molecular docking study of the active compounds was also done against EGFR, conferring good binding affinity and binding interactions. Further biological investigations may provide valuable insights towards exploring the therapeutic potential of the active compounds in future.
  • Recent advances in FDA-approved kinase inhibitors targeting lung cancer
    Vivek Panwar, Manini Bhatt, Dheeraj Bisht, Rajeshwar K. K. Arya, Deepak Kumar
    Handbook of Oncobiology from Basic to Clinical Sciences, 2024
  • Role and Development of Pharmaceutical Sciences and Sustainable Development Goals
    Vivek Panwar, Deepak Kumar
    Role of Science and Technology for Sustainable Future Sustainable Development A Primary Goal Volume 1, 2024
  • Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
    Vivek Panwar, Aishwarya Singh, Manini Bhatt, Rajiv K. Tonk, Shavkatjon Azizov, Agha Saquib Raza, Shinjinee Sengupta, Deepak Kumar, Manoj Garg
    Signal Transduction and Targeted Therapy, 2023
    The mammalian target of rapamycin (mTOR) is a protein kinase that controls cellular metabolism, catabolism, immune responses, autophagy, survival, proliferation, and migration, to maintain cellular homeostasis. The mTOR signaling cascade consists of two distinct multi-subunit complexes named mTOR complex 1/2 (mTORC1/2). mTOR catalyzes the phosphorylation of several critical proteins like AKT, protein kinase C, insulin growth factor receptor (IGF-1R), 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase (S6K), transcription factor EB (TFEB), sterol-responsive element-binding proteins (SREBPs), Lipin-1, and Unc-51-like autophagy-activating kinases. mTOR signaling plays a central role in regulating translation, lipid synthesis, nucleotide synthesis, biogenesis of lysosomes, nutrient sensing, and growth factor signaling. The emerging pieces of evidence have revealed that the constitutive activation of the mTOR pathway due to mutations/amplification/deletion in either mTOR and its complexes (mTORC1 and mTORC2) or upstream targets is responsible for aging, neurological diseases, and human malignancies. Here, we provide the detailed structure of mTOR, its complexes, and the comprehensive role of upstream regulators, as well as downstream effectors of mTOR signaling cascades in the metabolism, biogenesis of biomolecules, immune responses, and autophagy. Additionally, we summarize the potential of long noncoding RNAs (lncRNAs) as an important modulator of mTOR signaling. Importantly, we have highlighted the potential of mTOR signaling in aging, neurological disorders, human cancers, cancer stem cells, and drug resistance. Here, we discuss the developments for the therapeutic targeting of mTOR signaling with improved anticancer efficacy for the benefit of cancer patients in clinics.
  • Chromene derivatives as potassium channel openers or inhibitors
    Role of Chromenes in Drug Discovery and Development, 2023
  • Natural product-loaded nanoparticles for wound healing
    Anik Kumar Das, Himanshu Gandhi, Vivek Panwar, Ankit Awasthi, Sachin Kumar Singh, Deepak Kumar
    Nanotechnological Aspects for Next Generation Wound Management, 2023
  • Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies
    Yogesh Deswal, Sonika Asija, Deepak Kumar, Deepak Kumar Jindal, Gourav Chandan, Vivek Panwar, Sonia Saroya, Naresh Kumar
    Research on Chemical Intermediates, 2022
  • EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents
    Vivek Panwar, Kritika Mukherji, Manjunath Ghate, Deepak K. Jindal, Deepak Kumar
    Biomedical Translational Research Drug Design and Discovery, 2022

RECENT SCHOLAR PUBLICATIONS

  • Design, synthesis, in silico , anticancer evaluations of N -acylhydrazone derivatives as STAT3 inhibitors
    V Panwar, Y Rohila, A Singh, Meenakshi, B Singh, MK Gupta, M Garg, ...
    Future medicinal chemistry 17 (13), 1509-1519 , 2025
    2025
    Citations: 2
  • Application of Bioinformatics in Receptor Biology and Drug Discovery
    V Panwar, H Lalhlenmawia, D Bisht, RKK Arya, D Kumar
    Neuroreceptor Endocytosis and Signaling in Health and Disease, 457-473 , 2025
    2025
  • Molecular medicine and biomedical research in the era of precision medicine: New technologies, lifestyle interventions and personalized drug therapies for patient care
    RC Sobti, V Panwar, D Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine … , 2025
    2025
  • Recent advances in mammalian target of rapamycin targeted heterocyclic scaffolds as anticancer agents
    V Panwar, M Ghate, R Kumar, D Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine … , 2025
    2025
  • Synthesis, Evaluation and Docking Studies of Disubstituted N‐Heterocyclic Derivatives as Anticancer Agents
    SR Gopireddy, V Panwar, A Sarkar, M Jain, KB Tejaswini, ...
    Chemistry & Biodiversity 21 (12), e202401010 , 2024
    2024
  • Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents
    V Panwar, S SenGupta, S Kumar, PP Singh, A Kumar, S Azizov, ...
    In Silico Pharmacology 12 (2), 83 , 2024
    2024
    Citations: 11
  • Role and Development of Pharmaceutical Sciences and Sustainable Development Goals
    V Panwar, D Kumar
    Role of Science and Technology for Sustainable Future: Volume 1: Sustainable … , 2024
    2024
  • Recent advances in FDA-approved kinase inhibitors targeting lung cancer
    V Panwar, M Bhatt, D Bisht, RKK Arya, D Kumar
    Handbook of Oncobiology: From Basic to Clinical Sciences, 1277-1287 , 2024
    2024
    Citations: 4
  • Natural product-loaded nanoparticles for wound healing
    AK Das, H Gandhi, V Panwar, A Awasthi, SK Singh, D Kumar
    Nanotechnological Aspects for Next-Generation Wound Management, 319-331 , 2024
    2024
    Citations: 6
  • Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
    V Panwar, A Singh, M Bhatt, RK Tonk, S Azizov, AS Raza, S Sengupta, ...
    Signal transduction and targeted therapy 8 (1), 375 , 2023
    2023
    Citations: 1025
  • EGFR-targeted quinazoline clubbed heterocycles as anticancer agents
    V Panwar, K Mukherji, M Ghate, DK Jindal, D Kumar
    Biomedical translational research: drug design and discovery, 387-399 , 2022
    2022
    Citations: 7
  • Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies
    Y Deswal, S Asija, D Kumar, DK Jindal, G Chandan, V Panwar, S Saroya, ...
    Research on Chemical Intermediates 48 (2), 703-729 , 2022
    2022
    Citations: 108

MOST CITED SCHOLAR PUBLICATIONS

  • Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
    V Panwar, A Singh, M Bhatt, RK Tonk, S Azizov, AS Raza, S Sengupta, ...
    Signal transduction and targeted therapy 8 (1), 375 , 2023
    2023
    Citations: 1025
  • Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies
    Y Deswal, S Asija, D Kumar, DK Jindal, G Chandan, V Panwar, S Saroya, ...
    Research on Chemical Intermediates 48 (2), 703-729 , 2022
    2022
    Citations: 108
  • Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents
    V Panwar, S SenGupta, S Kumar, PP Singh, A Kumar, S Azizov, ...
    In Silico Pharmacology 12 (2), 83 , 2024
    2024
    Citations: 11
  • EGFR-targeted quinazoline clubbed heterocycles as anticancer agents
    V Panwar, K Mukherji, M Ghate, DK Jindal, D Kumar
    Biomedical translational research: drug design and discovery, 387-399 , 2022
    2022
    Citations: 7
  • Natural product-loaded nanoparticles for wound healing
    AK Das, H Gandhi, V Panwar, A Awasthi, SK Singh, D Kumar
    Nanotechnological Aspects for Next-Generation Wound Management, 319-331 , 2024
    2024
    Citations: 6
  • Recent advances in FDA-approved kinase inhibitors targeting lung cancer
    V Panwar, M Bhatt, D Bisht, RKK Arya, D Kumar
    Handbook of Oncobiology: From Basic to Clinical Sciences, 1277-1287 , 2024
    2024
    Citations: 4
  • Design, synthesis, in silico , anticancer evaluations of N -acylhydrazone derivatives as STAT3 inhibitors
    V Panwar, Y Rohila, A Singh, Meenakshi, B Singh, MK Gupta, M Garg, ...
    Future medicinal chemistry 17 (13), 1509-1519 , 2025
    2025
    Citations: 2
  • Application of Bioinformatics in Receptor Biology and Drug Discovery
    V Panwar, H Lalhlenmawia, D Bisht, RKK Arya, D Kumar
    Neuroreceptor Endocytosis and Signaling in Health and Disease, 457-473 , 2025
    2025
  • Molecular medicine and biomedical research in the era of precision medicine: New technologies, lifestyle interventions and personalized drug therapies for patient care
    RC Sobti, V Panwar, D Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine … , 2025
    2025
  • Recent advances in mammalian target of rapamycin targeted heterocyclic scaffolds as anticancer agents
    V Panwar, M Ghate, R Kumar, D Kumar
    Molecular Medicine and Biomedical Research in the Era of Precision Medicine … , 2025
    2025
  • Synthesis, Evaluation and Docking Studies of Disubstituted N‐Heterocyclic Derivatives as Anticancer Agents
    SR Gopireddy, V Panwar, A Sarkar, M Jain, KB Tejaswini, ...
    Chemistry & Biodiversity 21 (12), e202401010 , 2024
    2024
  • Role and Development of Pharmaceutical Sciences and Sustainable Development Goals
    V Panwar, D Kumar
    Role of Science and Technology for Sustainable Future: Volume 1: Sustainable … , 2024
    2024